Deloitte recognizes BICO as the third fastest-growing company in
The leading bio convergence company, BICO, announced today it ranked number three among
"The recognition is a confirmation of our rapid global growth and of the potential and interest for our bio convergence offering. I am thankful for the award, and very proud of the commitment of our team members that enables us to continue to create the future of health. I am excited to continue to accelerate and build this company for the future with the team" says Erik Gatenholm, CEO and co-founder BICO.
Founded in 2016, BICO has rapidly grown from one company with one office in
"We are excited to recognise and celebrate the companies in this year's Deloitte Sweden Technology Fast 50. The companies ranked, and the smart solutions and services they provide, reflect
For more information about Deloitte Sweden Technology Fast 50 please visit: fast50.se
For further information, please contact:
Phone (
Email: il@bico.com
Phone (US):
Riley Munks, PR Manager: (650) 863-6699
Alyssa D'Orazio, PR Manager: (617) 634-9601
Email: press@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on
About BICO
Founded in 2016, BICO (formerly
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
https://news.cision.com/bico-group/r/bico-ranked-top-three-fastest-growing-technology-company-in-sweden-by-deloitte,c3460970
https://mb.cision.com/Main/14960/3460970/1501798.pdf
(c) 2021 Cision. All rights reserved., source